|
|
|
| home > ebr > autumn 2020 > mesenchymal stem cells: the next generation of pain treatments |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
|
Pain is a major burden of disease and will likely increase as populations around the world grow older and the incidence of obesity increases.
The global market for pain therapies is large and growing, and is expected to be worth $77 billion by 2023 (1). Treatments for osteoarthritis alone will constitute a $10.1 billion market by 2024 (2).
However, pain is notoriously hard to treat and chronic pain – pain from diseases such as osteoarthritis, general knee, and back pain – even more so. Current treatment options for pain – often opioids or surgery – mostly treat the symptoms, not the source of the pain.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Wasdell Group strengthens PPFL business with ISO 13485 for medical devices
The Wasdell Group, a leading outsourcing partner to companies in
the pharmaceutical and biotech sector, has today announced that its
Dundalk, Ireland facility has been certified to comply with the ISO
13485 standard for medical device manufacturing.
The
ISO 13485 is an internationally recognised certification, ensuring that
the company’s quality management system complies to customer and
applicable regulatory requirements.
More info >> |
|
 |
White Papers |
 |
|
Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies
PCI Pharma Services
Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
.jpg)
